Showing results (171-180 of 208) with videos related to
Sort By:
Pageof 21
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.Gynecologic Oncology|June 28, 2017
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trialMartee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, et al.Cancer Research Communications|March 16, 2023
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with MelanomaRobert H I Andtbacka, Yan Wang, Robert H Pierce, et al.Current Oncology (Toronto, Ont.)|March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced MelanomaJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2024
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO GuidelineNadine Tung, Charité Ricker, Hans Messersmith, et al.JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.British Journal of Cancer|August 5, 2026
A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcomaSujana Movva, Victoria Allgood, Rashmi Chugh, et al.Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.Pageof 21